<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044732</url>
  </required_header>
  <id_info>
    <org_study_id>Avantis TER-08-06</org_study_id>
    <nct_id>NCT01044732</nct_id>
  </id_info>
  <brief_title>Third Eye Retroscope Randomized Clinical Evaluation</brief_title>
  <acronym>TERRACE</acronym>
  <official_title>Third Eye Retroscope Randomized Clinical Evaluation (The &quot;TERRACE&quot; Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avantis Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avantis Medical Systems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Third Eye® Retroscope® is a device that can be inserted through the instrument channel of
      a standard colonoscope to provide an additional, retrograde (or backward) view that reveals
      areas behind folds and flexures in the colon, and might detect additional polyps that cannot
      be seen with the colonoscope alone.

      Patients who participate as subjects in the study will undergo two complete colonoscopy
      procedures, a standard colonoscopy and a colonoscopy in which a Third Eye Retroscope is used
      along with the same colonoscope. Half of the patients will have the standard colonoscopy
      first followed by the Third Eye colonoscopy, and the other half will have the Third Eye
      procedure first.

      Results from the two groups will be analyzed and compared to determine the effectiveness of
      the Third Eye Retroscope for detecting additional adenomas and other polyps compared with the
      standard colonoscope alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colonoscopy is generally agreed to be the best method for detecting and removing
      pre-cancerous polyps, but some lesions can be missed, especially if they are located behind
      folds in the lining of the colon or behind flexures (sharp bends) in the colon.

      The Third Eye® Retroscope® is a device that can be inserted through the instrument channel of
      a standard colonoscope to provide an additional, retrograde (or backward) view that reveals
      areas behind folds and flexures in the colon. Previous studies have shown the device to be
      effective for detecting additional polyps that could not have been seen with the colonoscope
      alone.

      The purpose of this research is to compare the additional diagnostic yield obtained by using
      the Third Eye® Retroscope® vs. the diagnostic yield for the standard colonoscope alone in the
      context of a randomized, controlled study design.

      Patients who are scheduled for colonoscopy will be recruited to the study and randomized to
      one of two groups. Each patient will undergo two &quot;back-to-back&quot; procedures.

      Patients in Group A (study group) will undergo a standard colonoscopy followed immediately by
      a Third Eye colonoscopy.

      Patients in Group B (control group) will undergo a Third Eye colonoscopy followed immediately
      by a standard colonoscopy.

      Results from the two groups will be analyzed and compared to determine the effectiveness of
      the Third Eye Retroscope for detecting additional adenomas and other polyps compared with the
      standard colonoscope alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Detection Rates for Adenomas and for Total Polyps</measure>
    <time_frame>Acute - subjects were followed for the duration of the procedures, an average of 40 minutes.</time_frame>
    <description>Numbers of polyps and adenomas detected in first and second procedures for each group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Times for Withdrawal Phase and for Complete Procedure</measure>
    <time_frame>Acute - subjects were followed for the duration of the procedures, an average of 40 minutes.</time_frame>
    <description>For all examinations with each method (SC or TEC), mean time for withdrawal phase and mean time for total procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">448</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Group A - COLO, then TER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Complete examination with standard colonoscope (&quot;COLO&quot;) followed by complete examination with Third Eye Retroscope (&quot;TER&quot;) used in conjunction with standard colonoscope</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - TER, then COLO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Complete examination with Third Eye Retroscope (&quot;TER&quot;) used in conjunction with standard colonoscope, followed by complete examination with standard colonoscope (&quot;COLO&quot;) alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Third Eye Retroscope</intervention_name>
    <description>Device used with colonoscope to provide second, retrograde view of the colon</description>
    <arm_group_label>Group A - COLO, then TER</arm_group_label>
    <arm_group_label>Group B - TER, then COLO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is undergoing colonoscopy for screening, for surveillance in follow-up of
             previous polypectomy or for diagnostic workup;

          -  The patient must understand and provide written consent for the procedure.

        Exclusion Criteria:

          -  Patients with a history of colonic resection;

          -  Patients with inflammatory bowel disease;

          -  Patients with a personal history of polyposis syndrome;

          -  Patients with suspected chronic stricture potentially precluding complete colonoscopy;

          -  Patients with diverticulitis or toxic megacolon;

          -  Patients with a history of radiation therapy to abdomen or pelvis;

          -  Patients who are currently enrolled in another clinical investigation in which the
             intervention might compromise the safety of the patient's participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter D. Siersema, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Veterans Administration Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayside Endoscopy Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Milan</city>
        <zip>20089 Rozzano</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mark's Hospital</name>
      <address>
        <city>London</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Leufkens AM, DeMarco DC, Rastogi A, Akerman PA, Azzouzi K, Rothstein RI, Vleggaar FP, Repici A, Rando G, Okolo PI, Dewit O, Ignjatovic A, Odstrcil E, East J, Deprez PH, Saunders BP, Kalloo AN, Creel B, Singh V, Lennon AM, Siersema PD; Third Eye Retroscope Randomized Clinical Evaluation [TERRACE] Study Group. Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. Gastrointest Endosc. 2011 Mar;73(3):480-9. doi: 10.1016/j.gie.2010.09.004. Epub 2010 Nov 10.</citation>
    <PMID>21067735</PMID>
  </results_reference>
  <results_reference>
    <citation>Siersema PD, Rastogi A, Leufkens AM, Akerman PA, Azzouzi K, Rothstein RI, Vleggaar FP, Repici A, Rando G, Okolo PI, Dewit O, Ignjatovic A, Odstrcil E, East J, Deprez PH, Saunders BP, Kalloo AN, Creel B, Singh V, Lennon AM, DeMarco DC. Retrograde-viewing device improves adenoma detection rate in colonoscopies for surveillance and diagnostic workup. World J Gastroenterol. 2012 Jul 14;18(26):3400-8. doi: 10.3748/wjg.v18.i26.3400.</citation>
    <PMID>22807609</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2010</study_first_submitted>
  <study_first_submitted_qc>January 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2010</study_first_posted>
  <results_first_submitted>August 28, 2015</results_first_submitted>
  <results_first_submitted_qc>August 28, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 1, 2015</results_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Adenomas</keyword>
  <keyword>Polyps</keyword>
  <keyword>Miss rates</keyword>
  <keyword>Detection rates</keyword>
  <keyword>Colonoscope</keyword>
  <keyword>Third Eye Retroscope</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Aggregated, de-identified data to be published in peer-reviewed medical journal</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A - SC Followed by TEC</title>
          <description>Standard colonoscopy (SC) followed by Third Eye colonoscopy (TEC)
Third Eye colonoscopy: Examination of the colon with a Third Eye Retroscope used in combination with a colonoscope to provide second, retrograde view of the colon</description>
        </group>
        <group group_id="P2">
          <title>Group B - TEC Followed by SC</title>
          <description>Third Eye colonoscopy (TEC) followed by standard colonoscopy (SC)
Third Eye colonoscopy: Examination of the colon with a Third Eye Retroscope used in combination with a colonoscope to provide second, retrograde view of the colon</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inadequate bowel preparation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inability to reach cecum</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical error or malfunction</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat population, i.e., those who were actually examined during the study</population>
      <group_list>
        <group group_id="B1">
          <title>Group A - SC Followed by TEC</title>
          <description>Standard colonoscopy (SC) followed by Third Eye colonoscopy (TEC)
Third Eye colonoscopy: Examination of the colon with a Third Eye Retroscope used in combination with a colonoscope to provide second, retrograde view of the colon</description>
        </group>
        <group group_id="B2">
          <title>Group B - TEC Followed by SC</title>
          <description>Third Eye colonoscopy (TEC) followed by standard colonoscopy (SC)
Third Eye colonoscopy: Examination of the colon with a Third Eye Retroscope used in combination with a colonoscope to provide second, retrograde view of the colon</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="184"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="372"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="9.8"/>
                    <measurement group_id="B2" value="58.0" spread="9.7"/>
                    <measurement group_id="B3" value="57.8" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants in ITT population</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indication for colonoscopy procedure</title>
          <units>participants in ITT population</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surveillance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diagnostic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Detection Rates for Adenomas and for Total Polyps</title>
        <description>Numbers of polyps and adenomas detected in first and second procedures for each group</description>
        <time_frame>Acute - subjects were followed for the duration of the procedures, an average of 40 minutes.</time_frame>
        <population>Per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Group A - SC Followed by TEC</title>
            <description>Standard colonoscopy (SC) followed by Third Eye colonoscopy (TEC)
Third Eye colonoscopy: Examination of the colon with a Third Eye Retroscope used in combination with a colonoscope to provide second, retrograde view of the colon</description>
          </group>
          <group group_id="O2">
            <title>Group B - TEC Followed by SC</title>
            <description>Third Eye colonoscopy (TEC) followed by standard colonoscopy (SC)
Third Eye colonoscopy: Examination of the colon with a Third Eye Retroscope used in combination with a colonoscope to provide second, retrograde view of the colon</description>
          </group>
        </group_list>
        <measure>
          <title>Detection Rates for Adenomas and for Total Polyps</title>
          <description>Numbers of polyps and adenomas detected in first and second procedures for each group</description>
          <population>Per-protocol population</population>
          <units>Polyps or adenomas detected</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Polyps detected in first procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polyps detected in second procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adenomas detected in first procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adenomas detected in second procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Times for Withdrawal Phase and for Complete Procedure</title>
        <description>For all examinations with each method (SC or TEC), mean time for withdrawal phase and mean time for total procedure</description>
        <time_frame>Acute - subjects were followed for the duration of the procedures, an average of 40 minutes.</time_frame>
        <population>All subjects in study (i.e., Group A and Group B combined)</population>
        <group_list>
          <group group_id="O1">
            <title>All SC Procedures</title>
            <description>For all subjects in study (i.e., Group A and Group B combined), mean times for withdrawal phase and for total procedure during standard colonoscopies (SC)</description>
          </group>
          <group group_id="O2">
            <title>All TEC Procedures</title>
            <description>For all subjects in study (i.e., Group A and Group B combined), mean times for withdrawal phase and for total procedure during Third Eye colonoscopies (TEC)</description>
          </group>
        </group_list>
        <measure>
          <title>Times for Withdrawal Phase and for Complete Procedure</title>
          <description>For all examinations with each method (SC or TEC), mean time for withdrawal phase and mean time for total procedure</description>
          <population>All subjects in study (i.e., Group A and Group B combined)</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean withdrawal time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.58" spread="2.79"/>
                    <measurement group_id="O2" value="9.52" spread="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean total procedure time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.97" spread="9.90"/>
                    <measurement group_id="O2" value="20.87" spread="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24-72 hours post-procedure</time_frame>
      <desc>Assessed through follow-up telephone interview</desc>
      <group_list>
        <group group_id="E1">
          <title>Group A - SC Followed by TEC</title>
          <description>Standard colonoscopy (SC) followed by Third Eye colonoscopy (TEC)
Third Eye colonoscopy: Examination of the colon with a Third Eye Retroscope used in combination with a colonoscope to provide second, retrograde view of the colon</description>
        </group>
        <group group_id="E2">
          <title>Group B - TEC Followed by SC</title>
          <description>Third Eye colonoscopy (TEC) followed by standard colonoscopy (SC)
Third Eye colonoscopy: Examination of the colon with a Third Eye Retroscope used in combination with a colonoscope to provide second, retrograde view of the colon</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>With mean subject age of 57.8 years, population was younger than in some studies, so polyp prevalence might be below average.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jack Higgins, MD - Chief Medical Officer</name_or_title>
      <organization>Avantis Medical Systems</organization>
      <phone>6508239216</phone>
      <email>jhiggins@avantismedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

